i






Public Title Status Last Date Modified
A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan (APL-2)  in Patients with Paroxysmal Nocturnal Hemoglubinuria (PNH) . . . Ongoing 08 Mar 2021
A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients . . . Pending 20 Apr 2021
A Phase II Study of M5049 in COVID-19 Pneumonia (ANEMONE) Ongoing 18 Feb 2021
A Phase II, double-blind, controlled trial to assess the Safety and Immunogenicity of different schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in healthy subjects aged between 2 an . . . Completed 13 Apr 2020
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE) . . . Terminated 14 Aug 2020
A Phase II/III, Multicenter, Observer- Blinded, Randomized, Non-inferiority and Safety Study of Typhoid Conjugate Vaccine (EuTCV) Compared to Typar- TCV ® in Healthy 6 Months – 45 Years Aged Partic . . . Ongoing 17 Mar 2021
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα- Kinoid in Adult Subjects with System . . . Terminated 30 Apr 2021
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, . . . Ongoing 19 May 2020
A Phase III double-blind study to assess safety andefficacy of an RSV Maternal unadjuvanted vaccine,in pregnant women and infants born to vaccinatedmothers . . . Ongoing 15 Feb 2021
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metas . . . Ongoing 21 Sep 2020
A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-rel . . . Completed 01 Jul 2019
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squa . . . Ongoing 30 Oct 2020
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patie . . . Completed 18 May 2020
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung C . . . Ongoing 20 May 2020
A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in . . . Completed 13 Feb 2020
A phase III, multicenter, observer blind, randomized, controlled study to evaluate immuneequivalence of multi-dose formulation against single-dose formulation of Vi-DT Typhoidconjugate vaccine and saf . . . Pending 14 Jan 2020
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult patients with stages AJCC/UIC . . . Ongoing 12 Aug 2020
A Phase III, Open-label, Multicentre, Randomised Trial to Establish Safety and Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients Eligible to . . . Terminated 14 Apr 2020
A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutatio . . . Ongoing 12 Jan 2021
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicenter, Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage . . . Ongoing 11 Mar 2021
A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing M . . . Ongoing 12 Apr 2021
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma . . . Ongoing 11 Mar 2021
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy A . . . Ongoing 29 Jan 2021
A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to . . . Ongoing 14 Aug 2020
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab a . . . Ongoing 18 May 2020
©2021 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date